LONG MINI-FUTURE - BIOGEN IDEC | Real-time Bid/Ask 08:40:05 2024-06-24 EDT | ||
| 5.96 EUR / 6.07 EUR | +1.09% |
|
| Current month | -1.16% | ||
| 1 month | -6.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 5.88 | -1.18% |
| 24-06-21 | 5.95 | -3.25% |
| 24-06-20 | 6.15 | +5.13% |
| 24-06-19 | 5.85 | -1.35% |
| 24-06-18 | 5.93 | -4.97% |
Delayed Quote Börse Stuttgart
Last update June 24, 2024 at 07:42 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV2AX5 |
| ISIN | DE000VV2AX55 |
| Date issued | 2022-05-10 |
| Strike | 160.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.56 € |
|---|---|
| Lowest since issue | 2.96 € |
| Spread | 0.11 € |
| Spread % | 1.84% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224
USD
Average target price
284.6
USD
Spread / Average Target
+27.07%
- Stock Market
- Certificates
- Certificat
